What changed for Heart Disease
A plain English summary of what recently moved in the public data Voxsanity tracks for Heart Disease. Updated from government registries. Not medical advice.
How to read these changes: every figure on this page is the difference between two snapshots of what Voxsanity had tracked on each date. Voxsanity only began taking daily snapshots in July 2026 and is still ingesting the public registries, so a rise here is mostly our own coverage expanding rather than new research appearing. Read it as our tracked coverage growing, not as a claim about real-world research changing this fast: it overstates how much actually changed.
Comparing the two most recent snapshots, 27 July 2026 and 28 July 2026.
- Trials recruiting at Australian sites 13 to 14 (+1)
- Trials recruiting worldwide 606 to 624 (+18)
- Late-stage (Phase 3) trials 38 to 40 (+2)
- Trials on record 5,380 to 5,576 (+196)
Newly subsidised on the PBS
No medicines were newly subsidised on the PBS for Heart Disease in July 2026. Voxsanity tracks 14 PBS-subsidised medicines for this condition; none of them was listed for the first time this month.
Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.
Past updates
Tracking began in July 2026. Month on month changes will appear here once a second month of data has been recorded. Until then, the comparison above shows the most recent movement.
Recent trend
Weekly, most recent weeks (fills out to a monthly trend as history grows).
Recent trial results
The 30 most recent of 98 trials tracked for Heart Disease that have reported results to a public registry.
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
-
NCT04272060 · results posted 16 June 2026
According to the results reported on ClinicalTrials.gov, this trial enrolled 175 people in total, all of whom completed the study. Of those, 173 had a complete CT scan. The trial was measuring how accurately two types of heart artery imaging — a newer, high-resolution CT scan (called ultra-high-resolution CT, or UHR-CT) and a traditional invasive procedure where dye is injected directly into the arteries (called invasive coronary angiography, or ICA) — could correctly identify whether patients had a significant narrowing in their heart arteries. A separate pressure-based measurement taken duri...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT06791967 · results posted 12 May 2026
According to the results reported on ClinicalTrials.gov, this trial involved 68 people in total — 34 in a home-based walking group and 34 in a general health education group. The trial was measuring three things in people living with heart failure: depression levels (using a questionnaire called the PHQ-9, scored 0–27, where higher means more severe depression), frailty (using a scale called the CSHA-CFS, scored 1–9, where higher means greater frailty), and quality of life (using a questionnaire called the MLHFQ, scored 0–105, where higher means heart failure is having a bigger negative impact...
-
NCT07280208 · results posted 25 February 2026
According to the results reported on ClinicalTrials.gov, this trial involved 57 participants, all of whom were in a single group that received a "teach-back" education session — a method where patients are asked to repeat information back to check their understanding. All 57 participants completed the study. The trial was measuring two things: how participants' scores on a heart failure self-care behaviour questionnaire changed after the education session, and how many participants were admitted back to hospital within 30 days of being discharged. The reported data shows that, on average, par...
-
NCT05093933 · results posted 19 December 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT05093933) enrolled 3,053 people in the vericiguat group and 3,052 in the placebo group — just over 6,100 participants in total. The trial was measuring how often people experienced either a heart-failure-related hospitalisation or a death caused by a cardiovascular (heart or blood vessel) problem, whichever came first. It also tracked several related outcomes separately, including deaths from cardiovascular causes, deaths from any cause, and hospital admissions for heart failure. The reported data shows the following figu...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04986202 · results posted 27 August 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04986202) enrolled 711 participants across three groups: 235 people received a lower dose of AZD4831 (2.5 mg), 240 received a higher dose (5 mg), and 236 received a placebo (a dummy treatment with no active ingredient). The trial was measuring two main things: how participants felt about their heart symptoms using a questionnaire called the Kansas City Cardiomyopathy Questionnaire Total Symptom Score (a 0–100 scale where higher scores mean people felt better), and how far participants could walk in six minutes. These were...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02280941 · results posted 6 April 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 32 participants, with 31 completing the study and 1 not completing it. The trial involved a type of heart imaging called SPECT (Single Photon Emission Computed Tomography), and it was measuring how well SPECT scans could estimate blood flow through the heart muscle — a measurement known as myocardial blood flow (MBF). Specifically, the trial looked at two things: how closely SPECT's blood flow readings matched those from a more established imaging method called PET (Positron Emission Tomography), and how consistent SP...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05002088 · results posted 28 February 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 71 people in total — 57 in the main study group (called the "Primary Analysis Population") and 14 in a separate observation group (called the "Exploratory Registry Arm"). The trial was measuring outcomes related to a heart valve procedure, tracking things like deaths from any cause, serious stroke, severe bleeding needing a blood transfusion, kidney injury needing dialysis, and major complications with blood vessels. Of the 57 people in the main group, 7 completed the study, while 50 did not complete it; in the regist...
-
NCT02954341 · results posted 24 February 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT02954341) enrolled 321 people who had agreed to take part. Of these, 304 received the implanted wireless pressure sensor (called the "safety population"), and 299 had it successfully implanted (called the "effectiveness population"). The trial was measuring three main things: whether participants were free from serious complications related to the device or system; whether the pressure sensor continued to work without failing; and whether the rate of hospital admissions for heart failure changed over the year after the dev...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04509674 · results posted 7 January 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04509674) enrolled 6,522 people in total — 3,262 in the placebo group and 3,260 in the empagliflozin 10 mg group. The trial was measuring outcomes related to heart failure and death, primarily looking at how often participants were first hospitalised for heart failure or died from any cause. A range of secondary outcomes were also tracked, including total numbers of heart-related hospital admissions and deaths from various causes over time. The reported data shows that for the main (primary) outcome — the rate of first ho...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02777580 · results posted 4 October 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT02777580) enrolled 609 people who had suffered a heart attack. Participants were split into two groups: 405 people received a "pharmaco-invasive" approach (where clot-dissolving medication was given first, followed by a procedure to open the blocked artery) and 204 people received standard emergency angioplasty (a procedure to open the blocked artery directly, without prior medication). The trial was measuring several things: how well blood flow was restored to the heart, and how many people experienced serious events — su...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02884206 · results posted 6 August 2024
According to the results reported on ClinicalTrials.gov, this trial enrolled 706 people to begin with. Participants first went through two lead-in (run-in) periods — one taking valsartan and one taking LCZ696 — to check suitability before the main part of the study. After those run-in stages, 592 people moved into the main double-blind phase, where 295 were randomly assigned to LCZ696 (200 mg twice daily) and 297 to valsartan (160 mg twice daily). The trial was measuring whether LCZ696 had a different effect compared to valsartan on thinking and memory abilities over three years, as well as on...
-
NCT02325830 · results posted 5 August 2024
According to the results reported on ClinicalTrials.gov, this trial (called REDUCE FMR) enrolled 120 people in total — 87 in the treatment group (who received a small implanted device called the Carillon) and 33 in the control group (who did not). Of those, 70 people in the treatment group and 24 in the control group completed the study. The trial was measuring changes in a heart condition called functional mitral regurgitation — where a heart valve leaks blood backwards — by looking at the volume of blood leaking with each heartbeat, as well as other measures of heart function and physical ab...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03037931 · results posted 3 July 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT03037931) enrolled 3,065 people in total — 1,532 in the ferric carboxymaltose (an iron treatment given by infusion) group and 1,533 in the placebo group. The trial was measuring three things: how many participants died, how many were admitted to hospital for heart failure, and how far participants could walk in six minutes (a common way of measuring physical capacity in heart failure trials) at the start of the trial compared to six months later. The reported data shows that in the ferric carboxymaltose group, 131 partici...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03237858 · results posted 27 March 2024
According to the results reported on ClinicalTrials.gov, this trial — called MANAGE-HF Phase I — enrolled 200 people with heart failure. The study used a device called HeartLogic, which monitors patients remotely, and the goal of this phase was to test how well the device and its alert system could be built into everyday clinical care. All 200 participants were in a single group, meaning there was no comparison group. Of those who started, 144 people completed the study and 56 did not finish. The reported data shows that Phase I was described by the researchers as having no formal outcome mea...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04668144 · results posted 20 March 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT04668144) enrolled 77 people in total, split across three groups: one group received prasugrel alone (25 people), one received prasugrel and cangrelor together (25 people), and one received cangrelor followed by prasugrel (27 people). The trial was measuring platelet reactivity — in simple terms, how "sticky" the blood platelets were — using a device called VerifyNow, which gives a score in units called PRU (P2Y12 Reaction Units). A higher PRU score generally means platelets are more active. Nearly all participants complet...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04282148 · results posted 12 February 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT04282148) enrolled 105 participants, all of whom received a drug-eluting stent (a small mesh tube placed in a blocked artery to help keep it open, coated with medication). Of the 105 people who started the trial, 96 completed it and 9 did not. The trial was mainly measuring a combined event called "Target Lesion Failure" (TLF) — this means tracking whether participants experienced any of three things: death from a heart-related cause, a heart attack connected to the treated artery, or a procedure to re-open the same artery...
-
NCT03917459 · results posted 8 January 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT03917459) enrolled 27 men with chronic heart failure — 13 in the LCZ696 group and 14 in the Enalapril group. Both are medicines used in heart failure. The trial was measuring erectile function, self-reported frequency of sexual activity, and levels of a heart-related protein in the blood called NT-proBNP (a marker that can reflect how hard the heart is working). Most participants finished the study: 12 in the LCZ696 group and 13 in the Enalapril group. The reported data shows that erectile function was measured using a 15...
-
NCT01341964 · results posted 27 July 2023
According to the results reported on ClinicalTrials.gov, this trial involved 302 people split into two groups — 152 people in a higher-dose aspirin group and 150 people in a low-dose aspirin group. All participants completed the study, with no drop-outs recorded. The trial was measuring the blood concentration of the active form of a medicine called clopidogrel (a blood-thinning tablet) in people taking different doses of aspirin alongside it. The idea was to see whether the dose of aspirin made a difference to how much of the active form of clopidogrel appeared in the bloodstream. The report...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04767061 · results posted 3 July 2023
According to the results reported on ClinicalTrials.gov, this was a small clinical trial involving 9 people in total — 5 in one group and 4 in another. All 9 participants completed the trial. The study used what is called an "N-of-1" design, meaning each person took turns being on their usual dose of beta-blocker medication and then on a very low (minimally tolerated) dose, so each participant acted as their own comparison. The trial was measuring whether being on or off beta-blockers made a difference to things like daily step count, physical function, exercise capacity, and self-reported qua...
-
NCT04327024 · results posted 29 June 2023
According to the results reported on ClinicalTrials.gov, this trial (NCT04327024) enrolled 159 people across three groups — 53 received a combination of verinurad and allopurinol, 53 received allopurinol alone, and 53 received a placebo (an inactive treatment). The trial was primarily measuring changes in "peak VO2" — a standard test of how much oxygen the body can use during exercise, which gives an indication of heart and lung fitness — after 32 weeks. The trial also measured changes in a heart failure symptom questionnaire called the KCCQ (Kansas City Cardiomyopathy Questionnaire), where hi...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02924727 · results posted 22 June 2023
According to the results reported on ClinicalTrials.gov, this trial (NCT02924727) enrolled 2,834 people in the LCZ696 (sacubitril/valsartan) group and 2,835 people in the ramipril group — nearly 5,700 participants in total. The trial was comparing the two medicines in people with heart failure, and it was measuring how many participants experienced certain serious heart-related events, including death from a heart-related cause, being admitted to hospital for heart failure, or needing an unplanned outpatient visit for heart failure. The reported data shows that for the main (primary) outcome...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03775421 · results posted 7 March 2023
According to the results reported on ClinicalTrials.gov, this trial (NCT03775421) enrolled 111 participants, all of whom received a 10 mg daily dose of a medicine called macitentan. Only 1 participant was recorded as completing the study, while 110 did not complete it — though the data does not explain the reasons for this in detail. The trial was primarily focused on monitoring and recording medical events (called adverse events) that occurred during treatment, as well as tracking certain blood test results over time. There was no comparison group; everyone received the same treatment. The r...
-
NCT04394754 · results posted 23 December 2022
According to the results reported on ClinicalTrials.gov, this trial (NCT04394754) enrolled 182 people with heart failure across four groups: a Control group (44 people), and three groups using different digital health tools — BodyPort (46 people), Noom (46 people), and Conversa (46 people). The trial ran for 180 days and was primarily measuring changes in how participants rated their own quality of life, using a standard heart failure questionnaire called the Kansas City Cardiomyopathy Questionnaire (KCCQ). On this questionnaire, higher scores (up to 100) reflect better self-reported health, a...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02525939 · results posted 12 October 2022
According to the results reported on ClinicalTrials.gov, this trial (NCT02525939) enrolled 6,147 people in total — 3,071 in the dalcetrapib group and 3,076 in the placebo group (a placebo is a dummy treatment with no active ingredient). The trial was measuring whether dalcetrapib, compared to placebo, was associated with fewer serious heart-related events in people who had recently experienced a heart attack. The main thing researchers tracked was how long it took for a participant to have their first serious cardiovascular event, such as dying from a heart-related cause, having a non-fatal he...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT01125436 · results posted 10 August 2022
According to the results reported on ClinicalTrials.gov, this trial enrolled 64 people in total — 31 in a group receiving cholecalciferol (a form of vitamin D) plus calcium, and 33 in a group receiving a placebo (dummy treatment) plus calcium. The trial was measuring things like heart and lung fitness, leg muscle strength, and physical mobility in these participants. Of those who started, 19 people in the vitamin D group and 21 in the placebo group completed the study, with 12 people in each group not finishing. The reported data shows the following changes over the course of the trial. For t...
-
NCT03276728 · results posted 8 August 2022
According to the results reported on ClinicalTrials.gov, this trial (NCT03276728) tested a drug called AMG 986 against a placebo (an inactive dummy treatment) across three parts — Part A, Part B, and Part C. In total, 182 people started the trial. Part C focused specifically on people living with heart failure, split into two types: heart failure with reduced pumping ability (HFrEF) and heart failure with preserved pumping ability (HFpEF). The trial was primarily measuring how many participants experienced unexpected medical events (called adverse events) after taking the study drug or placebo...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04336995 · results posted 12 July 2022
According to the results reported on ClinicalTrials.gov, this trial enrolled 14 participants, all of whom completed the study — none dropped out. The trial involved an exercise-based intervention and was measuring something called **pulmonary transit time**, which is the number of seconds it takes for blood to travel through the blood vessels in the lungs. The reported data shows that the measured pulmonary transit time for the exercise group was **2.5 seconds**. It is worth noting that only this single primary outcome figure was reported in the submitted results. No secondary outcome measure...
-
NCT03057951 · results posted 6 June 2022
According to the results reported on ClinicalTrials.gov, this trial (NCT03057951) enrolled just under 6,000 adults — approximately 2,991 in the placebo group and 2,997 in the empagliflozin (10 mg) group. The trial was measuring whether empagliflozin, compared to a placebo (inactive pill), was associated with differences in rates of serious heart-related events in people with heart failure with preserved pumping function. The main thing researchers tracked was how often participants experienced either a cardiovascular-related death or a hospital admission for heart failure, whichever came first...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02230254 · results posted 12 May 2022
According to the results reported on ClinicalTrials.gov, this trial enrolled 101 people who were treated with a coronary stent called the PROMUS PREMIER Stent. The trial was measuring how well the stent could be delivered and positioned in a blocked heart artery — specifically whether it could be placed successfully without complications during the procedure, and whether the artery remained sufficiently open immediately afterwards. Of the 101 participants who started, 98 completed the study and 3 did not. The reported data shows that the main outcome — called "technical success" — was achieve...
-
NCT02100722 · results posted 20 January 2022
According to the results reported on ClinicalTrials.gov, this trial (NCT02100722) enrolled 1,500 people in total — 757 in a group that received a procedure called FFR-guided PCI (a way of opening blocked heart arteries using a wire-guided stent) and 743 in a group that had open-heart bypass surgery (CABG). The trial was measuring serious heart-related events over time, including death, heart attack, stroke, and the need for any further procedure to open blocked arteries. The reported data shows that for the main (primary) outcome — tracking how many people experienced any of those serious eve...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
See all 98 reported results for Heart Disease
These are the results as reported to the registry, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
What is coming
AI generated pipeline summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to NIH funding data, heart disease attracts a very large amount of public research funding from the United States, and that investment has remained broadly steady over time. For Australian patients, this is an encouraging sign. It suggests that heart disease continues to be treated as a serious global health priority, and that researchers around the world are actively supported in explor...
See the full Heart Disease page
Not medical advice. Voxsanity republishes public government health data in plain English. These figures describe research and registry activity, not the suitability of any treatment for any person. Trial status can change; always verify current status directly with the trial site and confirm Australian availability with your doctor.